Table 3.
MSI phenotypes grouped by the cancer development stage
| Disease stage | MSI-H | MSI-L | MSS | Total |
|---|---|---|---|---|
| I | 7 (53.8%) | 2 (15.4%) | 4 (30.8%) | 13 |
| II | 19 (43.2%) | 4 (9.1%) | 21 (47.7%) | 44 |
| III | 11 (29.7%) | 1 (2.7%) | 25 (67.6%) | 37 |
| IV | 0 | 0 | 3 (100%) | 3 |
| Sum | 37 | 7 | 53 | 97 |
MSI phenotypes grouped by the cancer development stage
| Disease stage | MSI-H | MSI-L | MSS | Total |
|---|---|---|---|---|
| I | 7 (53.8%) | 2 (15.4%) | 4 (30.8%) | 13 |
| II | 19 (43.2%) | 4 (9.1%) | 21 (47.7%) | 44 |
| III | 11 (29.7%) | 1 (2.7%) | 25 (67.6%) | 37 |
| IV | 0 | 0 | 3 (100%) | 3 |
| Sum | 37 | 7 | 53 | 97 |